Yondelis®: oral presentation of a comparative study in soft tissue sarcoma (T-SAR) between trabectedin versus best supportive care; and, a study in combination with immunotherapy. Lurbinectedin: the clinical advances made in Small Cell Lung Cancer, Ewing´s sarcoma, and breast cancer. Plitidepsin: overall survival data from the ADMYRE study in patients with relapsed/refractory multiple myeloma.
Madrid, 17th of May, 2018.- During the Congress of the American Society of Clinical Oncology (ASCO) that will be held form the 1st to the 5th of June in Chicago (USA), PharmaMar will present the data obtained from various clinical studies of the molecules Yondelis ®, lurbinectedin (PM1183) and plitidepsin.
Two studies carried out with Yondelis® (trabectedin) will be presented, including an oral presentation by the French Sarcoma Group on the results of aprospective phase III study comparing trabectedin versus best supportive care in patients with soft tissue sarcoma. And the design of the phase I/II safety and efficacy study using the triple combination of trabectedin, ipilimumab and nivolumab for the first line treatment of soft tissue sarcoma.
PharmaMar will also have data for lurbinectedin (PM1183), presenting the clinical advances made in indications such as Ewing´s sarcoma, breast cancer and small-cell lung cancer, which is
Article originally posted at